SEPTEMBER 9, 2020 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”) is completing the final stage of restructuring from a traditional business model to an agile, global online sales, research and development company. From executive staff to remote support, Isodiol has navigated extreme change amid COVID-19 resulting in many positive developments that the Company would like to announce to its shareholders and to the public.
To address shareholders’ inquiries about an announcement made on July 27, 2020 regarding filling the office of Chief Financial Officer, Andrew Alvis is appointed as interim CFO and Isodiol is currently working with a CPA consulting firm. As soon as the right candidate is selected, Isodiol will make an announcement.
As previously announced, Isodiol is experiencing a delay with financial reporting. This is an arduous process that normally would take between 1-2 months per quarter. With the departure of the former Chief Financial Officer and Isodiol’s restructuring amid COVID-19, delays are occurring. Isodiol sincerely appreciates our shareholders’ patience during this process. The Company is making swift progress to accomplish these reporting requirements and will make an update as soon as possible.
With the vision for long-term growth, Isodiol is making continual progress to expand its global sales distribution channels. Vitamin Shoppe, a distributor of Isodiol’s Iso-Sport products, recently announced CBD HQ is now available at over 570 locations, offering 20+ brands of trusted CBD hemp extract products.
In addition, Isodiol is in final discussions with a U.S and international sales distribution companies to accelerate growth.
RESEARCH AND DEVELOPMENT
Isodiol has continued its strong path into Latin America and work towards direct distribution into pharmacies. International compassionate care programs are distributing Isodiol’s Isodiolex and Purodiol products; these brands are not for sale in the U.S. These highly visible name brands are accelerating acceptance of hemp cannabidiol and hemp phytocannabinoids in medical and pharmaceutical markets.
OPERATIONS & COMMUNICATIONS
Isodiol has launched its new ecommerce website to fully transition from a traditional sales model to a global online fulfillment platform. The new functionality streamlines order processing for quick fulfillment and a consistent user experience across all devices. Consumer assurance includes a shopping guarantee by Dunn & Bradstreet with merchant verification and protection of $10,000 identity theft protection, $1,000 purchase guarantee, and $100 low price guarantee. Isodiol also implemented Trust Pilot amid the global pandemic to track customer satisfaction. Isodiol has received an excellent 4.5-star rating since implementing the program.
Corporate Communications & Public Relations – A public relations firm with nearly eight years of hemp cannabidiol (CBD) experience now heads Isodiol’s communications team. For media inquiries, contact [email protected]
Isodiol is proud to announce that the Company is in discussions with professional sports teams including basketball, hockey, and baseball. Isodiol is also committed to aiding retired athletes and Veterans battling brain injury. As details are finalized, Isodiol will share these details.
Isodiol sincerely appreciates its shareholders and supporters who are committed to the Company’s long-term vision for hemp CBD industry growth, product purity, and consistency for consumers worldwide. Isodiol trusts that this behind-the-scenes corporate update further emphasizes the Company’s ability to navigate forward progress amid a turbulent global business climate. Isodiol looks forward to sharing additional details on these industry advances shortly.
Andrew S. Alvis
President, Director and Interim CFO
Isodiol International, Inc.
CEO and Director
Isodiol International, Inc.
About Isodiol International Inc.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
ON BEHALF OF THE BOARD
ANDREW S. ALVIS
PRESIDENT, DIRECTOR & INTERIM CFO
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, its ability to repay the Debentures, and the future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release, that the Company may not be able to repay the Debentures in whole or in part, and that the Company may not otherwise be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.